Incyte Corporation has earned a US$ 19 million dollar milestone payment from Eli Lilly and Company based on the initiation of a phase-IIb clinical trial evaluating INCB28050 for the treatment of rheumatoid arthritis. This trial is being conducted by Eli Lilly as part of the exclusive worldwide license and collaboration agreement for Incyte's novel, oral, JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104.
This phase-IIb clinical trial is a global, dose-ranging, study expected to involve 270 patients with active rheumatoid arthritis and is open to enrolment via www.ClinTrials.gov -- NCT01185353.
Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation.